2017 PMI Network Verification Challenge "NVC3" Winner to Receive Service Project Conducted in 3D InSight™ Human Liver Microtissues
Deadline: December 31, 2017
About the NVC3 ChallengeThe 3rd sbv IMPROVER Network Verification Challenge (“NVC3”) aims to verify and enhance three unpublished causal biological network models (one for each metabolic phase) that include the signaling pathways leading to the activation of enzymes involved in the three phases of liver xenobiotic metabolism.
The NVC3 is expected to increase the networks' value and promote their use in research applications, including:
- Toxicology: to predict adverse outcomes and gain mechanistic understanding in response to exposures;
- Pharmacology: to establish drug mode of action and predict adverse drug effect;
- Personalized medicine: patient diagnosis and prediction of treatment outcome;
- Basic research: to build biological hypotheses from high-dimensional data sets such as those derived from microarray profiling studies.
Why should you participate in the NVC3?
Participants are part of a scientific community curating networks that describe key biological processes that may be key for the fields of systems biology and toxicology. In addition, the winner of the Challenge will be awarded a complementary study conducted in 3D InSight™ Human Liver Microtissues, contributing data generated in more physiologically relevant 3D models to the Network. Travel grants and gift cards are also available as secondary prizes.
It's not too late to participate!
About the sbv IMPROVER project
The sbv IMPROVER project, the websites and the Symposia are part of a collaborative project designed to enable scientists to learn about and contribute to the development of a new crowd sourcing method for verification of scientific data and results. The project is led and funded by Philip Morris International. The current challenges, website and biological network models were developed and are maintained as part of a collaboration with Selventa, Douglas Connect, SBX, OrangeBus and ADS. For more information on Philip Morris International’s research, please visit www.pmiscience.com.